nivolumab (Opdivo) -

nivolumab (Opdivo)
Information type: Guidance
Source: Scottish Medicines Consortium
Specialities: Cancers | Skin disorders
Summary
The SMC has not recommended nivolumab for use as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults. The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
UKMi comment
Separately, NICE technology appraisal 384 (February 2016) recommends nivolumab as a treatment option for advanced (unresectable or metastatic) melanoma in adults.
Related links: NICE TA 384